SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Biotechnology Cancer Cures
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: chirodoc who wrote (53)5/21/1999 1:28:00 AM
From: Miljenko Zuanic  Read Replies (1) of 226
 
Curtis:

Thanks for tip. Unfortunately I do not bet on OTC stocks, so will pass this one.

Several compounds (like antracycline) mimic cyclin-TK activation inhibition. However, to my knowledge flavopiridol is for now the only one who selective bind CDKx and it is at late stage (PII and PII/III) clinical trials. It seams that it do work.

Yes, I am positive on SUGN. 5416 and 6668 are very promising drugs in development. Also, SUGN haw few more TK targets, including cdk2.

Also I like OSIP, and recently SUPG (after PNU topoisomerase I inhibitor occupied oncologist interest) became interesting. Add IMCL (with some reservation) and MOGN (here I am conservative).

Miljenko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News